红外肝病治疗仪联合富马酸丙酚替诺福韦治疗慢性乙型肝炎的临床效果  

Clinical Effect of Infrared Liver Disease Treatment Device and Tenofovir Alafenamide Fumarate in the Treatment of Chronic Hepatitis B

作　　者：何雄志[1] HE Xiongzhi(Affiliated Hospital of Putian University,Putian 351100,China)

机构地区：[1]莆田学院附属医院,福建莆田351100

出　　处：《中外医学研究》2025年第6期36-39,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨采用红外肝病治疗仪联合富马酸丙酚替诺福韦(TAF)治疗慢性乙型肝炎(CHB)的临床效果。方法:选取2021年5月—2023年7月莆田学院附属医院收治的98例CHB患者作为研究对象,以随机数表法分成研究组(n=49)与对照组(n=49),对照组给予TAF治疗,研究组给予红外肝病治疗仪联合TAF治疗。比较两组临床疗效、病毒转阴率、肝功能、炎症因子。结果:治疗后,研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,研究组乙型肝炎病毒脱氧核糖核酸(HBV DNA)、乙型肝炎e抗原(HBeAg)转阴率高于对照组,差异有统计学意义(P<0.05);治疗3个月后,两组谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)水平下降,研究组低于对照组,差异有统计学意义(P<0.05);治疗3个月后,两组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平下降,研究组低于对照组,差异有统计学意义(P<0.05)。结论:红外肝病治疗仪联合TAF用于治疗CHB能够提高临床疗效,促进病毒学指标转阴,改善肝功能,缓解机体炎症反应。Objective:To explore the clinical efficacy of infrared liver disease treatment device and tenofovir alafenamide fumarate(TAF)in the treatment of chronic hepatitis B(CHB).Method:A total of 98 CHB patients admitted to the Affiliated Hospital of Putian University from May 2021 to July 2023 were selected as the study objects and divided into study group(n=49)and control group(n=49)by random number table method.The control group was given TAF treatment,and the study group was given infrared liver disease therapy combined with TAF treatment.The clinical efficacy,viral negative conversion rate,liver function and inflammatory factors of the two groups were compared.Result:After treatment,the total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the negative conversion rates of hepatitis B virus deoxyribonucleic acid(HBV-DNA)and hepatitis Be antigen(HBeAg)in the study group were higher than those in the control group,and the difference was statistically significant(P<0.05).After 3 months of treatment,the levels of alanine aminotransferase(ALT),aspartate transaminase(AST)and total bilirubin(TBIL)in two groups were decreased,and the study group was lower than the control group,the difference was statistically significant(P<0.05).After 3 months of treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in two groups decreased,and the study group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion:Infrared liver therapy instrument combined with TAF for the treatment of CHB can improve clinical efficacy,promote the negative transformation of virology indicators,improve liver function,and alleviate inflammation in the body.

关 键 词：慢性乙型肝炎 红外肝病治疗仪 富马酸丙酚替诺福韦 肝功能 

分 类 号：R51[医药卫生—内科学]